Bafna Pharmaceuticals Ltd (BAFNAPH) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

BSE: 532989 | NSE: BAFNAPH | Pharmaceuticals & Drugs | Small Cap

Bafna Pharma Share Price

111.80 4.30 4.00%
as on 06-Mar'26 16:59

DeciZen - make an informed investing decision on Bafna Pharma

Based on:

Overall Rating
Login to view analysis. M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Bafna Pharmaceuticals stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
27.36
Market Cap:
264.5 Cr.
52-wk low:
71.7
52-wk high:
205

Is Bafna Pharmaceuticals Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Bafna Pharma: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Bafna Pharmaceuticals Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % -0%-6%-7%-20.9%-3%10.6%8.4%16.1%9.6%6.3%-
Value Creation
Index
-1.0-1.4-1.5-2.5NA-0.2-0.40.2-0.3-0.6-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 85.36547.243.642.571.285.1115152146147
Sales YoY Gr.--23.9%-27.4%-7.5%-2.7%67.7%19.6%35.5%32.2%-4.3%-
Adj EPS -6.6-10.1-15.9-8.3-8.42.42.14.32.624.1
YoY Gr.-NANANANANA-10.6%102.4%-39.1%-24.7%-
BVPS (₹) 31.52217.18.8-18.62426.231.134.235.939.3
Adj Net
Profit
-12.2-18.8-37.7-19.7-25.6510.16.14.610
Cash Flow from Ops. -319.8-7.1-1.1-34.3-13.69.759.522.1-
Debt/CF from Ops. -27.14.2-6.6-42.2-0.1-11.14.62.61.3-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 6.1%28%19.7%-4.3%
Adj EPS NANA-2.4%-24.7%
BVPS1.5%NA11%4.9%
Share Price 12.6% -1.7% 6.3% 39.2%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
-18.7-35.9-88.2-64.4-5.510.38.414.985.610.9
Op. Profit
Mgn %
3.8-8-74.4-29.8314.51413.67.37.510.5
Net Profit
Mgn %
-14.4-28.9-80-45.2-4.77.85.88.743.26.6
Debt to
Equity
1.421.22.2-0.70.20.20.30.30.3-
Working Cap
Days
490603721682459193212208208220100
Cash Conv.
Cycle
247290236313407481798839

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Bafna Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 4.1 -10.5
TTM Sales (₹ Cr.) 147 42.5
BVPS (₹.) 39.3 0
Reserves (₹ Cr.) 70 -7
P/BV 2.84 0.00
PE 27.36 0.00
From the Market
52 Week Low / High (₹) 71.65 / 204.95
All Time Low / High (₹) 4.65 / 204.95
Market Cap (₹ Cr.) 264
Equity (₹ Cr.) 23.7
Face Value (₹) 10
Industry PE 42.2

Management X-Ray of Bafna Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Bafna Pharma - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Bafna Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales85654744427185115152146
Operating Expenses 83708257416173100141135
Manufacturing Costs1081011111413142023
Material Costs62503324163240638781
Employee Cost 6779101215161921
Other Costs 46311344671510
Operating Profit 3-5-35-1311012161111
Operating Profit Margin (%) 3.3%-8.0%-74.4%-30.0%2.9%14.5%14.0%13.6%7.3%7.5%
Other Income 11310012343
Interest 121172011223
Depreciation 4443345555
Exceptional Items 000000-200-2
Profit Before Tax -13-19-14-18-2651274
Tax -0-122000000
Profit After Tax -12-18-16-20-2651174
PAT Margin (%) -14.3%-28.4%-34.9%-45.2%-4.4%8.2%6.1%9.8%4.8%2.8%
Adjusted EPS (₹)-6.5-9.9-7.0-8.3-7.92.52.24.83.11.8
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 59414121-45762738185
Share Capital 1919242422424242424
Reserves 412217-3-73338505761
Minority Interest0000000000
Debt8082474631310202123
Long Term Debt3539232333581114
Short Term Debt45432323010512109
Trade Payables30232839131112283531
Others Liabilities 15201314607671115
Total Liabilities 185167128121718690130148153

Fixed Assets

Gross Block727273737480889599106
Accumulated Depreciation25293336394449545947
Net Fixed Assets 47434037353639404059
CWIP 00000102127
Investments 181811000000
Inventories1617119111520223028
Trade Receivables6854242561015414540
Cash Equivalents 3333820813
Others Assets 33324845102316171915
Total Assets 185167128121718690130148153

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity -320-7-1-34-14105922
PBT -13-19-14-18-2651274
Adjustment 1515-205-20468810
Changes in Working Capital -6242712-12-23-1-14-58
Tax Paid 000000-0-0-00
Cash Flow From Investing Activity -1-1438433-5-7-7-15-21
Capex -2-047-0-1-6-8-7-15-22
Net Investments 000000000-0
Others 1-14-943411-101
Cash Flow From Financing Activity 4-5-31-2712-510-11
Net Proceeds from Shares 041205500000
Net Proceeds from Borrowing 254-16-0-203-51214
Interest Paid -12-11-7-2-0-0-0-2-2-3
Dividend Paid 0000000000
Others -8-2-20-0-28100000
Net Cash Flow 0-00-06-7-28-62

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)-18.69-37.05-40.37-64.36N/A22.268.7916.759.525.01
ROCE (%)-0.04-5.98-6.97-20.9N/A10.628.4216.129.566.31
Asset Turnover Ratio0.470.380.320.350.440.90.961.051.10.97
PAT to CFO Conversion(x)N/AN/AN/AN/AN/A-2.3320.451.295.5
Working Capital Days
Receivable Days319335302205133405288104107
Inventory Days679110683896977676272
Payable Days191197280513586134106118134150

Bafna Pharmaceuticals Ltd Stock News

Bafna Pharmaceuticals Ltd FAQs

The current trading price of Bafna Pharma on 06-Mar-2026 16:59 is ₹111.8.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 05-Mar-2026 the market cap of Bafna Pharma stood at ₹264.5.
The latest P/E ratio of Bafna Pharma as of 05-Mar-2026 is 27.36.
The latest P/B ratio of Bafna Pharma as of 05-Mar-2026 is 2.84.
The 52-week high of Bafna Pharma is ₹204.9 and the 52-week low is ₹71.65.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Bafna Pharma is ₹147.4 ( Cr.) .

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals, incorporated in 1995, has been engaged in the manufacturing of pharmaceutical formulations for more than 3 decades. It exports its products to the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. It is known for providing consistent and unmatched service, supplying high-end pharmaceutical formulations to regulated and emerging markets. Additionally, the company has established itself as a competent player in the Contract Research and Manufacturing Services (CRAMS) industry. It has a WHO-GMP certified manufacturing facility. The facility is also accredited by EU GMP, UK MHRA, and TGA Australia for Non-Betalactum solid oral dosage forms. 

The company has established an in-house state-of-the-art Quality Control Lab at the its manufacturing facility. The lab features sophisticated and cutting-edge technology with advanced instruments to ensure rigorous quality control across all manufacturing processes. The facility has a dedicated containment area for manufacturing high potent drugs within the current manufacturing facility. This includes special features for ensuring protection of workers from cytotoxic agents, specialized equipment for handling highly potent formulations, and protocols to achieve safety, quality control, and compliance with stringent regulations. The company holds active product registrations in multiple countries.

Business area of the company:

The company is engaged in the manufacturing of pharmaceutical products. It exports its products to the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries.

Product Range:

  • Anti-Diabetic
  • Cardiovascular
  • Anti-Hypertensive
  • Bi-Layer Antihypertensive

Awards, accreditations and recognition

  • 1995: The company was awarded the WHO GMP.
  • 2005: The company bagged the ‘Best Supplier Award’ from the State Pharmaceutical Corporation of Sri Lanka.
  • 2009: The company received ISO 9001: 2000 Certificate of Registration for Manufacture and Export of Pharmaceutical products.
  • 2010: The company received ‘Best Supplier Award’ from the Government of Sri Lanka, Gold Quality Excellence Award 2009.
  • 2011: The company received Indian Drug Manufacturer's Association (IDMA) Quality Excellence Award 2010 - Silver Award under the category of Formulations Units.
  • 2011: The company received Excellence Award 2011 from IES.
  • 2011-12: The company received IDMA - Gold Award - Quality Excellence Award.
  • 2012-13: Bafna received the Prestigious Certificate Of Excellence From 16th State Pharmaceuticals Corporation (spc) Suppliers Convention 2013, Sri Lanka.
  • 2024-2025: Excellence in Pharma Exports by Times of India.
  • 2024-2025: Top 10 Finished Dosage Formulations Manufacturer by India Pharma Outlook.  
  • 2024-2025: Emerging Company of the Year 2025 - Healthcare by MSME Chamber of Commerce & Industry of India.
  • 2024-2025: MSME Best CEO 2025 by MSME Chamber of Commerce & Industry of India.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×